Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
3
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
3
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
clinical trials
diagnostics
europe blog main
europe top stories
hepatitis b
merck
microbiome
novartis
pfizer
purdue pharma
vertex pharmaceuticals
What
drug
3
×
bio
market
patients
roundup
acquisitions
advantages
bar
biggest
brings
build
buy
cancer
ceo
company’s
daniel
debut
dyne’s
eisai
expect
fda
flags
gamble
gilead
higher
incidence
lorcaserin
loss
marketing
medco’s
medicine
microbiome
mover
moves
new
openly
o’day
payers
physicians
pipeline
Language
unset
3
×
Current search:
cancer
×
drug
×
national
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone